Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Let there be no light damage

Aug. 20, 2018

Fasinumab topline phase III data presented in patients with chronic pain from OA of the knee or hip

Aug. 17, 2018

Brain immune cells mediate arthritic joint pain

Aug. 16, 2018

Izana Bioscience begins phase II proof-of-concept study of namilumab in ankylosing spondylitis

Aug. 14, 2018

New Janus kinase inhibitors synthesized at Leo Pharma

Aug. 14, 2018

Council of Scientific and Industrial Research divulges caerulomycin A analogues

Aug. 14, 2018

OrthoTrophix presents phase II results for TPX-100 in patients with knee osteoarthritis

Aug. 14, 2018

First patient treated in phase Ib study of resiniferatoxin for OA knee pain

Aug. 14, 2018

The exerkine apelin reverses age-associated sarcopenia

Aug. 9, 2018

U.S. researchers identify ITGA5 antagonists

Aug. 8, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...